Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex...
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.
- Conditions
- Interventions
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Bastyr University
- Target Recruit Count
- 19
- Registration Number
- NCT01839344
- Locations
- 🇺🇸
Bastyr Center for Natural Health, Seattle, Washington, United States
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-01-01
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 160
- Registration Number
- NCT01758471
- Locations
- 🇨🇳
Shanghai Clinic Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Institute for Endocrine and Metabolic Diseases, Shanghai, Shanghai, China
A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5570
- Registration Number
- NCT01709305
Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Services Hospital, Lahore
- Target Recruit Count
- 161
- Registration Number
- NCT01624116
- Locations
- 🇵🇰
Endocrinology Unit & Diabetes Management Centre, Services Hospital., Lahore, Pakistan
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 46
- Registration Number
- NCT01514838
Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients
- Conditions
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 165
- Registration Number
- NCT01490918
- Locations
- 🇰🇷
MedicalExcellence, Seoul, Korea, Republic of
Early Diabetes Intervention Program
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 219
- Registration Number
- NCT01470937
- Locations
- 🇺🇸
Indiana University Hospital GCRC, Indianapolis, Indiana, United States
Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 50
- Registration Number
- NCT01279512
- Locations
- 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2010-11-22
- Lead Sponsor
- Lotus Pharmaceutical
- Target Recruit Count
- 220
- Registration Number
- NCT01245166
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Exercise and Acarbose in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2010-11-22
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 62
- Registration Number
- NCT01244971
- Locations
- 🇸🇪
Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.